2025-09-23 ロイヤルメルボルン工科大学(RMIT)
Web要約 の発言:
<関連情報>
- https://www.rmit.edu.au/news/all-news/2025/sep/new-eyedrop
- https://pubs.acs.org/doi/10.1021/acsami.5c14464
- https://link.springer.com/article/10.1007/s43440-025-00778-7
標的指向型眼科薬物送達のためのルテイン製剤最適化:in vitroおよびin vivo知見 Optimizing Lutein Formulations for Targeted Ocular Drug Delivery: In Vitro and In Vivo Insights
Dao Nguyen,Sampa Sarkar,Thilini Thrimawithana,Terrence Piva,Charlotte E. Conn,Chi Luu,and Tien Huynh
ACS Applied Materials & Interfaces Published: September 9, 2025
DOI:https://doi.org/10.1021/acsami.5c14464
Abstract
Lutein is a plant pigment beneficial for eye health and for preventing retinal-related diseases. However, lutein is unstable, with low oral bioavailability. In this study, lutein fromMomordica cochinchinensiswas loaded into cubosome lipid nanocarriers, both neutral (lutein-MO) and cationic (lutein-MO-DOTAP); the release, stability, and retinal penetration of the drug were improved. The formulation was biocompatible on retinal cells, showed sustained release in cell culture media and simulated lachrymal fluid, and was stable at 25 °C for 90 days. The cationic formulation, lutein-MO-DOTAP, showed greater uptake into retina cells than unencapsulated lutein and conferred greater protection of retina cells against H2O2 stress. Lutein-MO-DOTAPs enhanced Nrf2 and HO-1 antioxidant genes and downregulated IL-6 inflammatory and VEGF-A angiogenesis genes. Lutein-MO-DOTAPs were detected in mice retina in vivo 1 day post intravitreal injection and 7 days after topical application as eyedrops. We have successfully created a more stable lutein formulation that could penetrate the back of the eye in the retina and be developed as a therapy to enhance eye health or mitigate eye diseases.
早期網膜症治療における非侵襲的薬理学的進展:生物活性ハーブ化合物、ポリマー送達システム、機能的標的の計算機支援バイオプロスペクティング Non-invasive pharmacological advances in early retinopathy treatment: bioactive herbal compounds, polymer delivery systems, and computational bioprospecting of functional targets
Christopher Busayo Olowosoke,Thilini Thrimawithana & Tien Huynh
Pharmacological Reports Published:28 August 2025
DOI:https://doi.org/10.1007/s43440-025-00778-7
Abstract
Anti-vascular endothelial growth factor (anti-VEGF), laser, and vitrectomy therapy are commonly used for the management of vision-threatening posterior eye disease (PED), but non-invasive alternatives have garnered increasing popularity as proactive preventative strategies for early retinopathy, such as targeted plant-based diets or herbal supplements. However, only some plants contain bioactive compounds that specifically target retinal degeneration and demonstrate potent pharmacological benefits that are cost-effective, safe, and accessible for at-risk individuals. This review pinpoints plant bioactive compounds, specifically polyphenols and carotenoids, that target retinopathy, with a focus on apoptotic, angiogenesis, inflammation, and oxidative pathways leading to visible, functional, and vascular macula improvements. Innovations accelerating therapeutic applications of these botanicals for ocular delivery were then explored. Finally, advancements in disease assessments and the computational methods for early retinopathy biomarker diagnosis and treatment, particularly designed to bio-prospect plant-based therapies, were also reviewed to guide future developments and address translational limitations.
